Takeda completes ARIAD buy
Takeda has now completion of its $5.2 billion acquisition of ARIAD Pharmaceuticals, in a deal that significantly boosts the Japanese drugmaer’s global cancer portfolio.
Read More
Tag: Ariad
Takeda shells out $5.2bn on Ariad
Takeda has announced its intention to buy US drugmaker Ariad for around $5.2 billion, in a move designed to boost its oncology offering.
Read More
- MHRA to open new Northern Ireland hub to strengthen UK‑wide life sciences collaboration
- Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial
- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
